When can dual antiplatelet therapy (DAPT) with medications such as aspirin and a P2Y12 inhibitor (e.g. clopidogrel) be resumed in a patient who has experienced a stroke with hemorrhagic conversion?

Resuming DAPT After Stroke with Hemorrhagic Conversion

In patients with stroke and hemorrhagic conversion who previously required DAPT for coronary indications, resume P2Y12 inhibitor therapy (preferably clopidogrel 75 mg daily) as soon as the hemorrhagic transformation is stable and bleeding risk is acceptable, typically within 5 days after endoscopic or radiographic confirmation of hemostasis, while continuing to hold aspirin or using aspirin monotherapy initially. 1, 2

Key Decision Points

Immediate Management

• Discontinue all antiplatelet therapy immediately when hemorrhagic conversion is identified on neuroimaging 1
• Perform urgent brain imaging (CT or MRI) to characterize the extent of hemorrhagic transformation and exclude ongoing expansion 1
• The decision to resume DAPT depends critically on the underlying indication: patients with recent coronary stents (especially within 12 months of ACS) face competing risks of stent thrombosis versus hemorrhagic expansion 1

Timing of Resumption Based on Coronary Risk

For High Ischemic Risk (Recent ACS with PCI within 12 months):

• Resume P2Y12 inhibitor therapy (clopidogrel 75 mg daily without loading dose) within 5 days after confirming hemorrhagic stability on repeat imaging 1, 2
• Consider holding aspirin for an additional 1-4 weeks, then resume at low dose (81 mg daily) if hemorrhagic transformation has resolved on follow-up imaging 1, 2
• Clopidogrel is strongly preferred over ticagrelor or prasugrel due to lower bleeding risk in this context 1, 2

For Lower Ischemic Risk (>12 months post-PCI or stable CAD):

• Delay resumption of any antiplatelet therapy for at least 7-14 days after hemorrhagic conversion 1
• When restarting, use aspirin monotherapy (81 mg daily) rather than DAPT unless there are compelling coronary indications 1

Contraindications to Early Resumption

• Do not resume DAPT if there is evidence of ongoing hemorrhagic expansion on serial imaging 1
• Prasugrel is absolutely contraindicated in patients with any history of stroke or TIA, including hemorrhagic conversion 1, 3
• Patients with large hemorrhagic transformations (>30% of infarct volume) or symptomatic intracerebral hemorrhage should have antiplatelet therapy delayed significantly longer, potentially weeks 1

Specific Antiplatelet Selection

P2Y12 Inhibitor Choice

• Clopidogrel 75 mg daily is the only acceptable P2Y12 inhibitor after hemorrhagic stroke 1, 2
• Do not use loading doses when resuming therapy after hemorrhagic conversion 1
• Ticagrelor and prasugrel carry unacceptable bleeding risks in this population 1, 3

Aspirin Considerations

• When resuming aspirin, use the lowest effective dose: 81 mg daily (range 75-100 mg) 1
• Consider delaying aspirin resumption longer than P2Y12 inhibitor resumption in patients with significant hemorrhagic conversion 1

Duration of Modified Therapy

• After hemorrhagic conversion, complete the minimum 12-month DAPT duration required for ACS/PCI by resuming therapy sequentially as bleeding risk permits 1
• In patients who develop hemorrhagic conversion >6 months after ACS, consider discontinuing DAPT entirely and using P2Y12 inhibitor monotherapy for the remainder of the 12-month period 1
• Add proton pump inhibitor therapy when resuming any antiplatelet regimen to reduce gastrointestinal bleeding risk 1

Monitoring Strategy

• Obtain repeat brain imaging (MRI preferred) at 3-7 days after initial hemorrhagic conversion before resuming antiplatelet therapy 1
• If hemorrhage is stable or resolving, proceed with sequential antiplatelet resumption as outlined above 1
• Schedule follow-up imaging at 30 days to confirm resolution before intensifying antiplatelet therapy 1

Critical Pitfalls to Avoid

• Never resume prasugrel after any stroke, including hemorrhagic conversion—this is an absolute contraindication with Class III evidence 1, 3
• Do not use loading doses of any antiplatelet agent when resuming therapy after hemorrhagic conversion 1
• Avoid resuming full DAPT simultaneously—restart P2Y12 inhibitor first, then add aspirin after confirming stability 1, 2
• Do not delay resumption indefinitely in high-risk coronary patients, as stent thrombosis carries mortality rates of 20-40% 1